Abstract PS10-23: Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer

医学 HER2/东北 安慰剂 内科学 中期分析 乳腺癌 临床试验 外科 多中心试验 随机对照试验 胃肠病学 癌症 多中心研究 病理 替代医学
作者
Snehal S. Patel,David B. McWilliams,Marisa Patel,Christine T. Fischette,Jaye Thompson,F. Joseph Daugherty
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (4_Supplement): PS10-23 被引量:7
标识
DOI:10.1158/1538-7445.sabcs20-ps10-23
摘要

Abstract Background: The final analysis of the GP2 prospective, randomized, placebo-controlled, single-blinded, multicenter Phase IIb trial investigating GP2+GM-CSF administered in the adjuvant setting to node-positive and high-risk node-negative breast cancer patients with tumors expressing any degree of HER2 (immuno-histochemistry [IHC] 1-3+) (NCT00524277) is now complete with 5 year follow-up. The trial enrolled HLA-A02 patients randomized to receive GP2+GM-CSF versus GM-CSF alone. The trial's primary objective was to determine if treatment with GP2, a HER2-derived peptide, reduces recurrence rates. Three and 4 year interim analyses for this trial and 3 Phase I studies showing GP2 to be safe and immunogenic have been previously reported by Mittendorf et al. Methods: Each enrolled and consented GP2-treated patient was scheduled to receive a total of 6 GP2+GM-CSF (500 mcg GP2: 125 mcg GM-CSF) intradermal injections every 3-4 weeks as part of the Primary Immunization Series (PIS) for the first 6 months and 4 GP2+GM-CSF booster intradermal injections every 6 months thereafter. Boosters were introduced during the trial, thus some patients did not receive all 4 boosters. Each enrolled and consented placebo patient was scheduled to receive a total of 6 GM-CSF only intradermal injections every 3-4 weeks for the first 6 months and 4 GM-CSF only booster intradermal injections every 6 months thereafter. Results: This 168 patient (ITT: n=180) basket trial across 16 clinical sites explored 96 HER2 3+ patients, who received a standard course of trastuzumab after surgery and subsequently completed the full PIS or placebo, starting the PIS at median 17.1 months after surgery, and 72 HER2 1-2+ patients, who did not receive trastuzumab after surgery and subsequently completed the full PIS or placebo, starting the PIS at median 10.8 months after surgery. Since GP2 is synergistic with trastuzumab, and the HER2 1-2+ patients did not receive trastuzumab, it was prespecified to compare recurrence rates ITT versus per protocol in these 2 distinct, independently reported populations, excluding those patients who did not complete the PIS. GP2 was shown to be well tolerated with no SAEs and elicited a potent immune response measured by local skin tests and immunological assays, which suggest peak immunity is reached at 6 months upon completion of the PIS. After 5 years of follow-up, the Kaplan-Meier estimated 5-year DFS rate in the 46 HER2 3+ patients treated with GP2+GM-CSF, if the patient completed the PIS, was 100% versus 89.4% (95% CI:76.2, 95.5%) in the 50 placebo patients treated with GM-CSF (p = 0.0338). The treated versus placebo HER2 3+ patients were well-matched, where 53% were stage T1, 41% were stages T2-T4, 55% were node positive, 58% were HR positive and received endocrine therapy, 77% received adjuvant radiation, 77% received adjuvant chemotherapy, and 89% received trastuzumab. After 5 years of follow-up, the Kaplan-Meier estimated 5-year DFS rate in the 35 HER2 1-2+ patients treated with GP2+GM-CSF, if the patient completed the PIS, was 77.1% (95% CI:59.5, 87.9%) versus 77.6% (95% CI:60.1, 88.2%) in the 37 placebo patients treated with GM-CSF (p = 0.9142). Conclusions: This study demonstrated that completion of the GP2+GM-CSF PIS safely elicited a potent immune response and reduced recurrence rates to 0% in HER2 3+ patients, who received a standard course of trastuzumab after surgery. A pivotal Phase III trial is being initiated to treat HER2 3+ patients in the neoadjuvant setting. GP2 also may be effective when used in parallel to trastuzumab based therapeutics or in combination with trastuzumab based therapeutics in HER2 1-2+ or other HER2 expressing cancers. Citation Format: Snehal S Patel, David B McWilliams, Marisa S Patel, Christine T Fischette, Jaye Thompson, F Joseph Daugherty. Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-23.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林鹏达发布了新的文献求助100
刚刚
fan完成签到,获得积分20
刚刚
星辰大海应助banban采纳,获得10
1秒前
cabbage完成签到,获得积分10
2秒前
小羊喝粥发布了新的文献求助10
3秒前
科研小民工应助Dzinver采纳,获得50
3秒前
纠纠完成签到,获得积分10
5秒前
5秒前
科目三应助灵巧谷波采纳,获得10
6秒前
焱焱完成签到 ,获得积分10
7秒前
bkagyin应助Nightfall采纳,获得10
9秒前
杨天水发布了新的文献求助10
10秒前
10秒前
10秒前
goldenfleece完成签到,获得积分10
11秒前
SYLH应助欢呼的莆采纳,获得10
11秒前
12秒前
12秒前
函王完成签到,获得积分10
13秒前
nice1025完成签到,获得积分10
14秒前
000000发布了新的文献求助10
14秒前
怀瑾完成签到,获得积分10
14秒前
AQI完成签到,获得积分10
14秒前
15秒前
机灵海云发布了新的文献求助10
15秒前
小羊喝粥完成签到,获得积分10
16秒前
tian完成签到,获得积分10
16秒前
MingY发布了新的文献求助10
16秒前
daoyi应助zy采纳,获得10
17秒前
fan发布了新的文献求助10
17秒前
17秒前
cabbage发布了新的文献求助10
18秒前
hs完成签到,获得积分10
18秒前
19秒前
钱钱发布了新的文献求助20
19秒前
nong12123发布了新的文献求助20
19秒前
Jialing发布了新的文献求助10
20秒前
wanci应助快研出来了采纳,获得10
21秒前
21秒前
21秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546689
求助须知:如何正确求助?哪些是违规求助? 3123769
关于积分的说明 9356697
捐赠科研通 2822394
什么是DOI,文献DOI怎么找? 1551413
邀请新用户注册赠送积分活动 723398
科研通“疑难数据库(出版商)”最低求助积分说明 713736